BiotechTube
Eternygen

Eternygen

Berlin, Germany· Est.
eternygen.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Eternygen is a private, preclinical-stage German biotech pioneering a novel approach to treating widespread metabolic and age-related diseases by targeting the SLC13A5 citrate transporter. The company leverages a virtual R&D model, collaborating with a network of academic scientists and CROs to advance its pipeline. With a focus on conditions like NAFLD/NASH, chronic kidney disease, diabetes, and osteoporosis, Eternygen aims to address significant unmet medical needs through a first-in-class mechanism. Its progress is evidenced by recent high-profile scientific publications and presentations at major conferences.

Metabolic DiseasesNon-alcoholic Fatty Liver Disease (NAFLD/NASH)Chronic Kidney DiseaseType 2 DiabetesObesityOsteoporosis

Technology Platform

Small molecule drug discovery targeting the sodium-coupled citrate transporter (NaCT/SLC13A5), a key regulator of cellular citrate metabolism implicated in energy regulation, lipogenesis, and inflammation across multiple tissues.

Opportunities

The company targets massive, underserved markets like NASH and CKD with a novel, upstream mechanism that could offer superior efficacy or disease-modification compared to existing therapies.
Its single-platform, multi-indication strategy allows for efficient resource allocation and creates multiple value inflection points across high-need therapeutic areas.

Risk Factors

Primary risks include the high translational risk of a novel, first-in-class target, where preclinical promise may not translate to human efficacy or safety.
The company also faces significant financing risk as a preclinical, virtual entity and intense competition from large pharma and biotechs in the metabolic disease space.

Competitive Landscape

Eternygen competes in crowded fields (e.g., NASH, diabetes) against large pharmaceutical companies and well-funded biotechs. Its key differentiator is the novel SLC13A5 mechanism, which is not widely pursued, potentially offering a unique efficacy profile. However, it must compete for funding, talent, and ultimately, clinical and commercial success against established players.

More companies in Small Molecule Drugs →More companies in Germany →